Trials / Completed
CompletedNCT00387517
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
An Eight-week Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / HCTZ (150/25 mg and 300/25 mg) in Comparison With HCTZ 25 mg in Patients With Essential Hypertension Not Adequately Responsive to HCTZ 25 mg Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 726 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren/HCTZ |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2006-10-13
- Last updated
- 2017-02-07
Locations
2 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT00387517. Inclusion in this directory is not an endorsement.